Sekizaki T, Kameda H, Nakamura A, Kuwabara S, Nomoto H, Cho KY, Ishi Y, Motegi H, Miyoshi H, Atsumi T.
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas Pituitary, in press IF = 3.8
{ 116件 }
Sekizaki T, Kameda H, Nakamura A, Kuwabara S, Nomoto H, Cho KY, Ishi Y, Motegi H, Miyoshi H, Atsumi T.
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas Pituitary, in press IF = 3.8
Nomoto H, Takahashi Y, Takano Y, Yokoyama H, Tsuchida K, Nagai S, Miya A, Kameda H, Cho KY, Nakamura A, Atsumi T.
Effect of switching to once-weekly semaglutide on non-alcoholic fatty liver disease: The SWITCH-SEMA 1 subanalysis Pharmaceutics, in press IF = 5.4, 5-Y IF= 6.0
第96回日本内分泌学会学術集会 愛・内分泌賞 大江 悠希先生
Favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi Pharmaceutics, in press IF 6.525
アメリカ内分泌学会（ENDO 2023）Outstanding Abstract Award 桑原 咲先生
Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yoichi M. Ito, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study Diabetes, Obesity and Metabolism, in press
IF: 6.408
Nomoto H.
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes
IF：4.560
Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference – A novel education model after the COVID pandemic – Journal of the Endocrine Society, in press.
IF：なし
Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.
Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1
study)
Diabetes Obes Metab, in press
IF = 6.408